Amneal Pharmaceuticals (AMRX) Proxy filing summary

Executive summary

• Announced a definitive agreement to acquire Kashiv BioSciences, a vertically integrated biopharmaceutical company specializing in complex and biologic medicines, with over $900M invested since 2013 and 600+ employees globally.

• Kashiv has received marketing authorization for multiple biosimilars and operates state-of-the-art facilities in the US and India, with significant planned expansion in drug substance capacity by 2028.

• The acquisition aims to strengthen the pipeline with 20+ biosimilars across various therapeutic areas, with several products expected to be commercialized or approved between 2027 and 2030.

Voting matters and shareholder proposals

• Shareholder approval is required for the proposed acquisition of Kashiv BioSciences, with proxy materials to be filed and distributed for voting.

Board of directors and corporate governance

• Directors and certain executive officers are identified as participants in the proxy solicitation for the acquisition, with further details available in the 2026 annual meeting proxy statement.